CA2372912A1 - Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia - Google Patents

Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia Download PDF

Info

Publication number
CA2372912A1
CA2372912A1 CA002372912A CA2372912A CA2372912A1 CA 2372912 A1 CA2372912 A1 CA 2372912A1 CA 002372912 A CA002372912 A CA 002372912A CA 2372912 A CA2372912 A CA 2372912A CA 2372912 A1 CA2372912 A1 CA 2372912A1
Authority
CA
Canada
Prior art keywords
neoplasia
cyclooxygenase
inhibitors
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002372912A
Other languages
French (fr)
Other versions
CA2372912C (en
Inventor
Karen Seibert
Jaime Masferrer
Gary B. Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
G.D. Searle & Co.
Karen Seibert
Jaime Masferrer
Gary B. Gordon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G.D. Searle & Co., Karen Seibert, Jaime Masferrer, Gary B. Gordon filed Critical G.D. Searle & Co.
Priority claimed from CA002267186A external-priority patent/CA2267186C/en
Publication of CA2372912A1 publication Critical patent/CA2372912A1/en
Application granted granted Critical
Publication of CA2372912C publication Critical patent/CA2372912C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. In particular, the invention describes the method of preventing and treating epithelial cell neoplasia in a subject, said method comprising treating the subject with a therapeutically--effective amount of a compound of Formula I. (see formula I) wherein A, R2 and R3 are as described in the specification.
CA002372912A 1997-10-14 1997-10-14 Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia Expired - Fee Related CA2372912C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002267186A CA2267186C (en) 1996-10-15 1997-10-14 Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002267186A Division CA2267186C (en) 1996-10-15 1997-10-14 Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Publications (2)

Publication Number Publication Date
CA2372912A1 true CA2372912A1 (en) 1998-04-23
CA2372912C CA2372912C (en) 2008-12-02

Family

ID=4163412

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002372912A Expired - Fee Related CA2372912C (en) 1997-10-14 1997-10-14 Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Country Status (1)

Country Link
CA (1) CA2372912C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014430A1 (en) * 2002-08-07 2004-02-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
WO2005048942A2 (en) * 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
US7470715B2 (en) 2005-12-22 2008-12-30 Pfizer Inc. Estrogen modulators

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014430A1 (en) * 2002-08-07 2004-02-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
WO2005048942A2 (en) * 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
WO2005048942A3 (en) * 2003-11-13 2006-03-30 Pharmacia Corp Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
US7470715B2 (en) 2005-12-22 2008-12-30 Pfizer Inc. Estrogen modulators

Also Published As

Publication number Publication date
CA2372912C (en) 2008-12-02

Similar Documents

Publication Publication Date Title
CA2267186A1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
WO2001066564A3 (en) Gamma-secretase inhibitors
WO1998028282A3 (en) OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
AU7490900A (en) Chemical compounds and compositions and their use as cathepsin s inhibitors
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
WO2002046171A3 (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
CA2273841A1 (en) 3-thiocarbamoylpyrazole derivatives as pesticides
CA2208018A1 (en) Sulfonamides
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
WO2001032652A3 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
NO984470L (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
CA2214131A1 (en) Trisubstituted phenyl derivatives
WO1998036730A3 (en) Compositions for treating acne rosacea
WO2003030886A3 (en) Allylamides useful in the treatment of alzheimer's disease
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
AU2002232400A1 (en) Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
WO2000040583A3 (en) Imidazo[4,5-c]-pyridine-4-on-derivatives
WO1998027930A3 (en) New use of aminopiperazine derivatives
CA2188796A1 (en) Heterocyclylbenzonitriles
AU5050601A (en) Phosphine compounds and their use as tanning agents, corrosion inhibitors and biocides
CA2372912A1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
GR1003490B (en) Novel pharmaceutical compositions comprising a salt of paraxetine
CA2270301A1 (en) Hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for their preparation
WO1995018122A3 (en) Heteroarylpyrroles

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141014